2019
Clinical evaluation of the oral gonadotropin-releasing hormone-antagonist elagolix for the management of endometriosis-associated pain
Taylor HS, Dun EC, Chwalisz K. Clinical evaluation of the oral gonadotropin-releasing hormone-antagonist elagolix for the management of endometriosis-associated pain. Pain Management 2019, 9: 497-515. PMID: 31434540, DOI: 10.2217/pmt-2019-0010.Peer-Reviewed Original ResearchConceptsEndometriosis-associated painPain symptomsEstrogen-dependent chronic inflammatory diseaseSevere endometriosis-associated painCurrent medical treatment optionsNonmenstrual pelvic painPelvic pain symptomsMedical treatment optionsChronic inflammatory diseasePathophysiology of endometriosisRole of estrogenEstrogen suppressionCentral sensitizationPelvic painTreatment optionsClinical evaluationInflammatory diseasesPainClinical developmentHigh dosesLow dosesElagolixUS FDAEndometriosisSymptomsEndometriosis
Flores V, Taylor H. Endometriosis. DeckerMed Family Medicine 2019 DOI: 10.2310/fm.1005.Peer-Reviewed Original ResearchPelvic painSurgical therapyGrowth of endometriosisReproductive-age womenRole of estrogenDiagnosis of endometriosisGynecologic diseaseRetrograde menstruationCommon symptomsEndometriosis managementTreatment optionsPatient preferencesAge womenEndometriosisMolecular pathwaysPainPatientsAberrant gene expressionInfertilityTherapyDiseaseGene expressionDyspareuniaEstrogenEtiologyEndometriosis
Flores V, Taylor H. Endometriosis. DeckerMed Medicine 2019 DOI: 10.2310/im.1005.Peer-Reviewed Original ResearchPelvic painSurgical therapyGrowth of endometriosisReproductive-age womenRole of estrogenDiagnosis of endometriosisGynecologic diseaseRetrograde menstruationCommon symptomsEndometriosis managementTreatment optionsPatient preferencesAge womenEndometriosisMolecular pathwaysPainPatientsAberrant gene expressionInfertilityTherapyDiseaseGene expressionDyspareuniaEstrogenEtiology
2008
Morphological and Functional Features of Hepatic Cyst Epithelium in Autosomal Dominant Polycystic Kidney Disease
Alvaro D, Onori P, Alpini G, Franchitto A, Jefferson DM, Torrice A, Cardinale V, Stefanelli F, Mancino MG, Strazzabosco M, Angelico M, Attili A, Gaudio E. Morphological and Functional Features of Hepatic Cyst Epithelium in Autosomal Dominant Polycystic Kidney Disease. American Journal Of Pathology 2008, 172: 321-332. PMID: 18202196, PMCID: PMC2312356, DOI: 10.2353/ajpath.2008.070293.Peer-Reviewed Original ResearchMeSH KeywordsAgedBlotting, WesternCell ProliferationCiliaCyst FluidCystsEpitheliumEstradiolFemaleFluorescent Antibody TechniqueHumansImmunohistochemistryInsulin-Like Growth Factor ILiver DiseasesMaleMicroscopy, Electron, ScanningMiddle AgedPolycystic Kidney DiseasesReceptor, IGF Type 1Receptors, EstrogenConceptsAdult autosomal dominant polycystic kidney diseaseInsulin-like growth factor-1Autosomal dominant polycystic kidney diseaseDominant polycystic kidney diseaseEstrogen receptorCyst epitheliumPolycystic kidney diseaseCyst fluidCell nuclear antigenKidney diseaseGrowth hormone receptorHormone receptorsNuclear antigenHepatic cyst fluidHuman cyst fluidEpithelial cellsRole of estrogenGrowth factor-1ADPKD patientsEstrogen antagonismImmunohistochemical expressionLarge cystsSmall cystsTherapeutic strategiesMTS proliferation
2005
Hormone Therapy Does Not Affect Depression Severity in Older Women
Goldstein KM, Harpole LH, Stechuchak KM, Coffman CJ, Bosworth HB, Steffens DC, Bastian LA. Hormone Therapy Does Not Affect Depression Severity in Older Women. American Journal Of Geriatric Psychiatry 2005, 13: 616-623. PMID: 16009738, DOI: 10.1097/00019442-200507000-00010.Peer-Reviewed Original ResearchConceptsHormone therapyDepressive symptom severityHT useOlder womenDepression severitySymptom severityWomen age 60 yearsNon-HT usersSevere depressive symptomsRole of estrogenAge 60 yearsTreatment of depressionCross-sectional analysisHT usersAntidepressant medicationMenopausal symptomsUnadjusted analysesImproving MoodDepressive symptomsDepression scoresTreatment studiesBeneficial effectsGood healthSeverityBaseline data
2000
Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial
Mulnard R, Cotman C, Kawas C, van Dyck C, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Gamst A, Grundman M, Thomas R, Thal L, Study F. Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial. JAMA 2000, 283: 1007-1015. PMID: 10697060, DOI: 10.1001/jama.283.8.1007.Peer-Reviewed Original ResearchConceptsEstrogen replacement therapyModerate Alzheimer's diseaseSecondary outcome measuresReplacement therapyAlzheimer's diseaseOutcome measuresClinical trialsPlacebo-controlled clinical trialMini-Mental State Examination scoreAlzheimer's Disease Cooperative StudyPrevention of ADClinical Dementia Rating ScaleClinical Global ImpressionPrimary outcome measureTreatment of mildSmall clinical trialsRole of estrogenState Examination scoreDementia Rating ScaleCGIC scoresEstrogen groupPlacebo groupControlled TrialsFunctional outcomeGlobal Impression
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply